

Dermapharm Group Equity Story

April 2025

AGENDA

- 1. At a glance
- 2. Segment Branded pharmaceuticals
- 3. Segment Other healthcare products
- 4. Segment Parallel import business
- 5. Selected M&A transactions
- 6. Financials
- 7. Outlook
- 8. Financial calendar





1 At a glance

Image: Günther Fotodesign

Dermapharm Group The Management Team





Dr. Hans Feldmeier

Chief Executive Officer

>20 years company affiliation







Dr. Andreas Eberhorn

Chief Marketing Officer

as of 1 Sep 2022

SANDOZ A Novartis





Christof Dreibholz

Chief Financial Officer Chief Compliance Officer

as of 1 Nov 2022



Dermapharm at a glance

ARKET SELECTION

Pharmaceutical excellence "Made in Europe"...

... based on an integrated business model ...

			BRANDI	ED PHARMACEUTICALS				
	Dermapharm AG	nite actis*	Str	rathmann 🛞 SUI		gopharma 🔬		
	Product development	Regulatory Affairs	Production	Quality management	Logistics	Sales & distribution		
			OTHER H	EALTHCARE PRODUCTS				
>	Weissen wei	MELASAN°	mibeTec	EUROMED	Cemelle JCan	ndoro ethics		
	Product development	Regulatory Affairs	Production	Quality management	Logistics	Sales & distribution		
			PARALI	LEL IMPORT BUSINESS				
>								
	Regulatory Affairs	Sourcing	Repackaging	Quality management	Logistics	Sales & distribution		

- Rapidly growing manufacturer of branded pharmaceuticals
- Focus on selected markets in Europe with an increasing international footprint

Dermapharn


- Flexible pharmaceutical manufacturing and distribution capabilities
- Highly efficient in-house R&D process
- ~400 APIs¹ (active pharmaceutical ingredients) and >1,300² MA (marketing authorisations) branded pharmaceuticals in Germany and abroad
- Leading producer of other healthcare products
- Sixth-largest parallel import business in Germany based on revenue
- Continuous business optimisation and growth by successful M&A
- Worldwide Ø 3,610³ employees

NTERNATIONALISATION

Dermapharm at a glance Highly attractive and profitable product portfolio




... with focus on selected therapeutic areas




1 Until 2022 Branded pharmaceuticals and other healthcare products, Herbal extracts, Parallel import business, from 2023 onwards Branded pharmaceuticals, Other healthcare products, parallel import business 2 EBITDA Margin adjusted for non-recurring costs.

Total Revenue



Dermapharm Equity Story 2025 6



Dermapharm Dermapharm with increasing international footprint with $\sim 3.600^{1}$ employees worldwide Candoro ethics allergopharma Cernelle 💩 mibeTec mibe ۲ SWEDEN mibe GmbH Arzneimittel STRATHMANN SUN-FARM Trommsdorff *<u><u></u></u>UROMED* 💩 mibeTec Montavit Dermapharm MELASAN[®] acis *EUROMED* HASAN • Arko virues a Science HASAN DERMAPHARN Dermapharm Equity Story 2025 8

1 as of 30 Sept 2024. 2 30%.

Credible growth strategy

based on three pillars



In-house development

- Own development of new products based on a pipeline of 60¹ ongoing development projects
- Five development centers specialised in different product groups
- In-house key development and authorisation processes including designing and funding of clinical trials
- Focus on...
 - ... expanding portfolio of branded pharmaceuticals
 - ... further developing allergy therapy product range
 - ... developing science-based food supplements and phyto extracts



Internationalisation

- Well established subsidiaries in Austria, Switzerland, Croatia, Poland and Ukraine
- Self-formed subsidiaries in Italy and Spain
- Further expansion to Western- and Southern Europe: market access to France, Spain, Portugal, Italy, Benelux via Arkopharma
- Expansion of international presence via international distribution of the successful Dermapharm products through own subsidiaries and distribution partners
- Global roll-out of medical devices bite away[®] and Herpotherm[®] to > 15 European countries, USA and Japan



M&A activities

Dermapharr

- Non-organic growth based on comprehensive M&A know-how for new authorisations, products and companies
- Since founding of Dermapharm in 1991, product offerings have been continuously developed through successful acquisitions
- Track record in successful integration into the existing business
- Centralisation of branded pharmaceuticals at the main production and logistic hub in Brehna
- Continuous examination of further M&A opportunities



2 Segment Branded pharmaceuticals

Dermapharm's USP: excellent market positioning



due to stringent focus on selected niche markets

	Originators	Dermapharm	Generic companies
		Dermapharm	EN MINIMERICA INCOMESION EN MINIMERICA INCOMESION SANDOZ A Novartis Division
Portfolio	Patented products (Solitaire)	 Branded products ~70% off-patent originator products and preparations without patents¹ 	Generics
Markets	 Attractive regulatory environment	 Dermapharm`s selected German	 Challenging regulatory
	for originators	markets are protected	conditions for generics
Price pressure	 No price pressure, after first year	 Limited price pressure and	 Significant margin pressure
	of product launch and thereafter	low priority for	and high priority for
	price negotiations with SHIs	SHI rebate contract	SHI rebate contracts
Regulatory barriers	 High regulatory barriers	 High regulatory barriers therefore not	 Low regulatory barriers for
	to entry, due to	very attractive for new entrants and	new patent-free high volume
	patent protection	strongly positioned market players	pharmaceuticals
Development risk	 Only achieved under high	 Low risk development	 Low risk development
	development risk and	with relatively	with relatively
	significant investments	high investments	low investments


1 Source: ApoFusion Sell-Out, by turnover (ApU PPU),

based on German brand portfolio (by value) including original preparations for which patent protection no longer exists and preparations without patents.

Leading branded pharmaceuticals manufacturer



in selected therapeutic areas




Leading branded pharmaceuticals manufacturer



in selected therapeutic areas

Market Dermapharm 2024




Source: Company information, Individual market definition by Dermapharm on the basis of Insight Health data – ApoFusion, sell out data Market position: Market definitions include molecules and ATC-markets of Dermapharm portfolio, Rx, OTC and health products and include competitors with more than €100.000k yearly revenue in the respective market | Market (share) growth based on molecules and ATC-markets of Dermapharm portfolio, Rx, OTC and health products, ex factory prices. Gross sales in the segment "Branded pharmaceuticals and other healthcare products" in Germany.

Leading positions in attractive markets

protected by significant barriers to entry





Highly effective sales organisation and strategy

securing customer access and highest number of prescriptions





1 Kassenärztliche Bundesvereinigung, ABDA, internal data | All figures refer to Germany as of 31 Dec 2024;

Pharmaceutical firms selling over 50,000 units per year in Germany, sell out data IH-Galaxy Apo Fusion insight health - MAT Dec 2024 in tsd. Units.

Dermapharm follows an integrated R&D philosophy

Dermapharm

with a highly efficient development process

Strong internal R&D capabilities...

~350

R&D employees (~10% of all employees)¹

~400

APIs

Typical process duration⁴



R&D in % of revenue²

>1,300

Marketing authorisations across Europe and Asia³



(PHARMACEUTICA	L) DEVELOPMEN	F		CLINICAL STUDY		REGULATORY APPROVAL
	12 – 24	months			6 – 24 months		18 – 24 months
API sourcing	Formulation	Analytics	Pilot scale	Non interventional	Bioequivalence	Therapeutic equivalence	
Typical cost per development phase €200 – 600 k				€100 – 1,500 k		€ 30 – 50 k per country	

1 as of 31 Dec 2024 excl. axicorp

2 Own R&D work capitalised as a percentage of revenues from branded pharmaceuticals for the fiscal year ended 31 December 2024

3 Separate marketing authorisations may be granted for one active pharmaceutical ingredient, based on different galenic forms in different European countries.

4 depending on products | Photo: Günther Fotodesign.

Pharmaceutical and operational excellence



based on integrated value chain and "one-stop-shop" approach

Low – medium risk product development State-of-the-art, flexible production

~95%

Development success rate in Brehna

4 months – 8 years

Time to market



>90%

In-house production¹ at Allergopharma even 100%

>150k units

Produced per day

Marketing authorisations from own R&D

93² in 2024

Product launces / renewals

ntegrated logistics and service



Strong quality and

regulatory

management

+008



24h/48h

Pharmacies & hospitals/ Wholesalers supply time

in >50

Countries



3 Segment – Other healthcare products

Other healthcare products Expansion by M&A transactions





- Leading manufacturer of herbal food supplements "made in France"
- Focus on phytotherapy, natural health and natural beauty
- #1 market leader in France
- Internationalisation in Western and Southern Europe

euromed

- A leading producer of herbal extracts and natural active ingredients
- 98% of international revenues
- Export in >50 countries
- mainly for the phytopharma and food supplements market



- Research, development, manufacturing and distribution of pollen extracts for urology
- Effective treatment of chronic prostatitis and chronic pelvic pain
- Access to the active ingredient of our Strathmann product "Pollstimol"
- Distribution channels in Asia and Europe



- Market Leader for dronabinol in Germany and Austria
- Candoro ethics develops, produces and markets natural & synthetic dronabinol (API)
- Application in pain and palliative medicine, oncology and neurology, covering a broad spectrum of chronic and severe diseases

Euromed in Spain

with well-known international B2B business (acquired in 2019)

瀛

CUROMED Group



A leading producer of herbal extracts and natural active ingredients mainly for the phyto-pharma and food supplements market



Production of food supplements







Okeechobe, Florida

>50 years of experience

>**300** customers

>200 Stock keeping units

98% International sales

>**800** tn Extracts sold



Synergy effects in the areas of supply of

Dermapharm

natural active ingredients and product development



Phyto-pharmaceuticals and food supplements

AB Cernelle in Sweden



Founder and leader of extracting pollen for medical use (acquired in 2021)

Development of herbal medicines from high-quality pollen extracts and of the API Cernitin[™]







Pollen

API Cernitin[™]

Cernitol[®]Novum

Synergy effects

- Access to the important active ingredient of Strathmann product "Pollstimol"
- Development of further distribution channels in Asia and Europe



- A pharmaceutical company with research, development and manufacture of drugs in urology, with a special focus on benign prostate enlargement and chronic prostatitis
- Cernelle with a long tradition of innovative product development
- Cernelle sells the medicines under the brand names Ceritin[™], Cernilton[®], Cernitol[®] and Cernitol[®]Novum through external distributors in Asia and Europe
- Cernilton[®] is one of only two medicines approved worldwide for the effective treatment of chronic prostatitis as well as chronic pelvic pain
- In the wake of an increasing ageing population, these therapeutics offer solid growth potential

Candoro ethics

Candoro ethics



Acquisition of market leader in European cannabinoid-based pharmaceuticals in 2022

- Research, ...
- ... development,
- ... production and
- ... distribution of dronabinol, a natural cannabinoid-based active pharmaceutical ingredient (API)
- Pioneer with > 25 year of expertise in dronabinol in Germany
- Leading market positions also in Austria, Switzerland and Denmark
- Key therapeutic areas: pain and palliative treatment, oncology and neurology, addressing a broad spectrum of chronic and severe illnesses
- Successful relocation of production from Neumarkt and Höchst to Friedrichsdorf
- GMP-compliant production of pharmaceutical quality dronabinol from cannabis flowers made in Germany

Expansion into a full-range supplier in the medical cannabis sector



Dronabinol

Focus on concentrate due to new court ruling

Target group: doctors & pharmacies



Extracts

Product launch of medically relevant extracts in 2025

Target group: doctors



Niche market, used as anticonvulsant or antiepileptic

Target group: doctors & pharmacies



Flowers

Product launch to participate in enormous growth market thanks to broad product range

Target group: doctors & pharmacies



4 Segment – Parallel import business

Image: Günther Fotodesign

axicorp – a leading parallel import business in Germany with significant market share

Sales through a unique call center in Germany



>138 tsd. outbound-calls p.a. / ~80% pharmacy coverage

Direct pharmacy business with 3 partner programs ...

	1. First Class Partner				
Pharmacies	2. Premium Clients				
Filamacies	3. Development Cli	ents			
and additio	nal services	Depending on sales			
Discounting in	payload procedure	Delivery rhythm			
		Marketing support			

axicorp is one of top-10 parallel import companies in Germany¹ based on sales – gross sales 2024 in €m, total market €4.2bn



Dermapharm

Parallel import business – pillar of the German health system

Free trade within the European Union, with significant existing price differences

Legal requirements in Germany



Legal promotion of imports to relieve the German health system:

- Introduction of a price efficiency clause to oblige pharmacies to achieve a savings target of 2% by selling inexpensive imported products
- Exceptions: products with generic competition as well as biopharmaceuticals and parenteral cytostatics
- A price advantage must be given

Price advantages offer imports with a price difference to the original of at least

15% at a selling price up to €100

€15 at a selling price between **€100** - **300**

5% with a selling price of above €300



Dermapharn

Significant import countriesSignificant export countries

Integrated business model

Leverage of axicorp's sales platform for selected OTC products



warehousing, buffer stock

Low margin

Branded pharmaceuticals and other healthcare products

No specific customer advice required

Strong, broad and low-cost

distribution via call center

contract manufacturing for

axicorp led to significant

sales increase of relevant

Start of licensing and

OTC products

30% coverage

Pricing and rebates offer significant value to pharmacies with stable and long-term sourcing conditions

axicorp Leverage sales **Direct marketing**





5 Selected M&A transactions

Arkopharma at a glance – consolidated since Jan 2023

Producer of food supplements in Western / Southern Europe





- Food supplements "made in France"
- headquartered in Carros close to Nice
- Market access to Western-Europe
- ~40 % international sales

Fully integrated platform with a unique expertise in plant sourcing, manufacturing and natural product developments



Montavit – consolidated as of July 2023

A pioneer in catheter gels based in Absam, Austria







Familyowned business with own R&D and manufacturing capabilities for pharmaceuticals and medical devices

Focus on therapeutic areas

- Urology
- Gynecology
- Allergy therapy
- Herbal pharmaceuticals

Core competencies

- production of sterile gels
- Global player in coal tablets production and processing

Pioneer in catheter gels since 1971

 >90% market share with "Cathejell" in Austria





Represented in >80 countries worldwide via distributors

Allergopharma – an attractive acquisition in March 2020

Diagnosis for tailored treatment of allergies



Expansion in diagnosis and therapy of allergic diseases



100% share in a leading provider of specific subcutaneous immunotherapy (SCIT) for Type I-Allergies such allergic rhinitis and asthma





Portfolio of Allergy Immunotherapy (AIT) products





Presence in the EU



Direct presence

Partners

Presence in Asia



Headquarter in Reinbek



Attractive acquisitions in January 2018

Well-known originator and OTC products to boost our direct payer share





Vitamins / Minerals / Food • Supplements







mibeTec – a high-quality medical devices manufacturer

Hyperthermic product portfolio is available in 25 countries worldwide

Herpotherm[®]

herpotherm

Constant demand: 90% of people are affected by the incurable herpes virus, thereof 1/3 will need regular treatment







bite away[®]

centres due to global warming/increased rain

Increasing demand: Number of mosquito types is rising in urban

Pharmacies



5-sterne-garantie.de

INISCH GETESTE

R@SSMANN 😹 Müller

Key Accounter





Pharmacies



MADE IN

5-sterne-garantie.de




6 Financials

Steady organic revenue growth supported by M&A activities


Market access with increasing direct payer share

Total Revenue €m



Revenue by market access²

Branded pharmaceuticals & parts of other healthcare products



1.181 1.135 1,025

1 Until 2022 Branded pharmaceuticals and other healthcare products, Herbal extracts, Parallel import business, from 2023 onwards Branded pharmaceuticals, Other healthcare products, Parallel import business

from 2023 onwards Branded pharmaceuticais, Other healthcare products, Parallel Im

2 Gross sales | 3 Including private health insurances


Source: Insight Health (NV3, Apofusion), Applied services, internal data (Hospitals and other "special" customers, which cannot be shown by market research data).

Dermapharm

Dermapharm Group



Continuous revenue growth and increased profitability of sustainable ongoing business



Continuous revenue growth of 4.0% to €1,180.8m, driven by


- Strong organic growth in underlying branded pharmaceuticals products both, in Germany and abroad
- acquisition of Montavit (cons. as of July 2023)
 more than compensating for
- decline in Arkopharma and
- vaccine business based on pandemic preparedness program in 2024 and going forward
- Adj. EBITDA increases by 1.7% to €315.6m (+10.2% to €308.9m at reported level). EBITDA margin excl. vaccine business improves by +1.4%-pts. from fix cost leverage, while the lower vaccine business leads to 0.6%-pts. decline of reported EBITDA-margin

1 EBITDA FY 2023 adjusted for non-recurring costs of €29.9m in connection with the acquisition of Arkopharma and Montavit, consulting costs in connection with further acquisition efforts, restructuring of fitvia and Candoro ethics NM, impairment of Corat, deconsolidation effects of fitvia, bellavia, mibe UK, Corat and Gynial, income from the realisation of a negative difference (Montavit). EBITDA FY 2024 adjusted for non-recurring costs of €6.7m, thereof €1.9m in connection with additional costs for property in Carros, €2.2m in connection with share reduction in Wellster Healthtech Group GmbH and €1.2m in connection with the relocation of Candoro ethics GmbH NM and THC Pharm GmbH to Friedrichsdorf | Group EBITDA also includes EBITDA from reconciliation of -€5.3m (Group Holding).
2 EAT = Earnings after taxes.

Dermapharm Group



Top line growth driven by branded pharmaceuticals with disproportionate impact on results and margin



Revenue and **adj. EBITDA increase** by **+8.1%** and **13.4%** respectively, driven by

- German core and international business
- strong growth of Allergopharma

Earnings after Taxes (EAT) increased by €22.5m to **€19.1m**, mainly due to the higher financial result following a favourable valuation of the interest SWAPs


1 EBITDA Q4 2023 adjusted for non-recurring costs of €5.5m in connection with Arkopharma (PPA effects), deconsolidation effects (Corat and Gynial) and income from the realisation of a negative difference (Montavit) | Group EBITDA also includes EBITDA from reconciliation of -€1.3m (Group Holding).

EBITDA Q4 2024 adjusted for non-recurring costs of €0.5m, in connection with additional costs for property in Carros | Group EBITDA also includes EBITDA from reconciliation of -€1.4m (Group Holding).

Branded pharmaceuticals



Strong organic growth more than compensates for expiring vaccine business



Revenue increase of 9.8% to €585.1m, following

- strong organic growth
 - in DACH region and
 - international business as well as
 - at Allergopharma
- more than compensating for phasing out of vaccine production since Q2 2023
- successful launch of self developed products
- with >10% organic growth in existing portfolio

Adjusted **EBITDA increased** by **10.3%** to **€264.8m**, reported **EBITDA increased** by **13.3%** to **€259.4m**, driven by

Excluding the vaccine business and Montavit EBITDA and EBITDA margin increased, the latter to >45%


1 EBITDA FY 2023 adjusted for non-recurring costs of €11.0m in connection with M&A related items (M&A-related expenses, initial consolidation and deconsolidation effects as well as expenses an income in connection with the sale of shares)

EBITDA FY 2024 adjusted for non-recurring costs of €5.4m in connection with additional costs for property in Carros, share reduction in Wellster Healthtech Group GmbH.

Other healthcare products



Lower consumer spending drives decline in Arkopharma revenues in H1 2024



Revenue declined by -4.7% to €354.4m, driven by


- high sell-in to French pharmacy market due to an aboveaverage price increase and new product launches in H1 2023
- Working capital management at French pharmacies in H1 2024 (reducing inventory)
- growing competition resulting in increase in volume and price pressure
- Candoro ethics weaker than expected due to relocation to Friedrichsdorf and challenging market environment
- stable development of Euromed and Anton H
 übner

EBITDA decreased by -24.8% to €57.7m (adjusted, reported EBITDA by -2.2% to €56.5m)

Parallel import business



Rebates to SHI companies and unfavourable changes in product mix leave their mark



Revenues increased by +4.5% to €241.3m, driven by

good product availability in parallel import market


EBITDA decreased to -€1.6m

Positive revenue effects were offset by

- higher mandatory discount payments due to portfoliorelated increases in health insurance rebates
- increased personnel and operating expenses

Earnings after tax (EAT)

Increase mainly impacted by organic growth and positive financial result





Dermapharm Group

EBITDA adjustments significantly lower vs. prior year

€m F	Y 2024	FY 2023	
Share reduction	2.3		Wellster decline in participation triggering a GW reduction partly offset by increased (share in) equity
Additional cost of property	1.8		Arkopharma (Carros)
Relocation to Friedrichsdorf	1.2		Candoro ethics
Derecognition of PPA effects from sale of property	0.7		Property in Berlin (Branded pharmaceuticals)
Others	0.7		
PPA-effects		17.6	Arkopharma
Acquisition costs		8.7	Arkopharma, Candoro ethics, Wellster, Montavit
Impairment		6.6	Corat
Profit from acquisiton at a price below market value (reducing earnings)		-5.8	Montavit
Deconsolidation & Restructuring		2.8	fitvia, bellavia, mibe UK
Total	6.7	29.9	




1 rolling 12M adjusted EBITDA as of 31 Dec 2024.

2 Interest Cover = adj. EBITDA / interest expenses (long and short-term loans).

Net debt reduction

by €67m since Dec 2023 proofs ability of underlying business to generate cash



- Ongoing net debt reduction in 2024 driven by
 - €50m repayment of term loan B and
 - €38.5m repayment of promissory note loan
- Net debt / adjusted EBITDA¹: 2.8 in line with syn loan provisions (FY2023: 3.0)
- Comfortable interest cover ratio² of 5.9
- Increasing equity ratio, due to favourable Group result



Balance Sheet of Dermapharm Group



Total assets €m

2,160 2,160 2,080 2.080 394 Current 327 630 Current liabilities 593 assets 1.145 Non-current 1.221 liabilities 1.530 1.487 608 545 Non-current Equity assets 31 Dec 2023 31 Dec 2024 31 Dec 2023 31 Dec 2024

€m

Total equity and liabilities • Non-current assets decreased due to

- Regular amortisation of intangible assets identified as part of the PPA and due to the sale of a plot of land and building in Berlin
- First full-year depreciation of Montavit's property, plant and equipment in 2024

Other current assets decreased since

- VAT prepayments received in previous year
- Cash and cash equivalents declined
- Change in equity mainly due to increase in retained earnings which resulted primarily from the consolidated net profit for financial year 2024 less the dividend paid for the preceding financial year
- Equity ratio increased to 29.2% of total assets
- Decrease in financial liabilities due to €50m repayment of term loan B and promissory note loan (€38.5m)
- Reduction in current liabilities because of lower current VAT liabilities

1 revenue excluding BioNTech

44

Dermapharm Equity Story 2025

rease by	5 uays	compa

moderate DPO increase by 5 days compared

to 2023

Cash cycle favourably impacted by

backdrop of tight supply chains

• Underlying growth in revenues¹

Inflationary production cost increases (labour and materials)

Generally higher buffer stock to secure

ability to deliver products against the

Higher **inventory** levels driven by

Dermapharm

€m FY 2024 FY 2023 YoY Inventory 343.4 320.8 +7.0%Trade receivables 100.9 90.9 11.0% Trade payables 94.8 86.6 +9.5%Net working capital 349.5 325.1 +7.5%Days 107 DIO 106 +0.9%DSO 31 29 +6.9%DPO 64 59 +8.5% Cash cycle 74 76 -2.6%

Net working capital increase by >7% mainly driven by higher inventory levels,

Working capital


cash cycle improves by 2 days

Strong cash flows and cash conversion

High cash conversion of 63.8%

Cash flow and cash conversion¹

€m and in % of Group EBITDA



 CF from operating activities declines by 8.2% largely because of -€27.6m change in net working capital

Dermapharn

- Decline in CF from investing activities mainly due to
 - Acquisitions of Arkopharma and Montavit in the previous year
 - €34.4m recurring CapEx (FY 2023:
 €38.7m) exceeding depreciation charges of fixed assets
- Free cash flow: €171.8m in FY 2024 (FY 2023: -€196.0m)

Cash Flow from operating activities



	FY 2024	FY 2023	YOY	
EBT	172.0	106.0	+66.0	
Depreciation / amortisation fixed assets & reversal of impairment	86.8	101.8	-15.0	 Reversal of depreciation charges Impairment loss recognised in the previous year in relation to development costs for mibeTec's product, bite away
Profit sharing of at-equity investments	-1.5	7.2	-8.7	 Reversal of at-equity results of Hasan and Wellster
Interest expense / income	41.9	65.7	-23.8	 Reversal of interest result including changes in the value of the capitalized interest rate swap
Provisions for employee benefits, other non-cash items, gain / loss on disposal of non-current assets	6.5	-3.0	+9.5	 Largely resulting from the reversal of non-cash items mainly including the reduction of the participation in Wellster in 2024 and deconsolidation effects regarding fitvia, bellavia and mibe UK in 2023 and PPA related losses from the disposal of a property in Berlin
Subtotal	305.7	277.7	-28.0	
Working capital (assets and liabilities)	-20.4	7.2	-27.6	 Higher inventory level driven by revenue growth, production cost increase, buffer stocks and phasing of purchases Inventory increase partly offset by higher payables
Income tax payments	-83.8	-65.4	-18.4	
CF from operating activities	201.4	219.4	-18.0	

Earnings before tax (Group EBT)

Result decreases due to increase in interest expenses

Earnings before tax (EBT)¹ €m



EBT increased by **+62.3%** to **€172.0m** translating to an EBT **margin** of **14.6%**

Significantly higher **EBT result** mainly driven by

Dermapharr

- higher (unadjusted) EBITDA (+€28.6m)
- reduced depreciation (-€14.0m) and
- significantly increase of +€32.0m in financial result to -€44.9m in 2024 (2023: -€76.9m)



7 Outlook

Image: Günther Fotodesign

Dermapharm Equity Story 2025 49

Outlook 2025

Our strong products, further internationalisation and sustainable synergies are the basis for continuous EBITDA improvement



- Organic growth in branded pharmaceuticals with focus on strengthening key brands, new launches from in-house development and portfolio expansion in European affiliates
- Planned decline in parallel import revenues and profit due to focus on high-margin product portfolio
- Outlook for 2025 reflects general austerity measures in the healthcare sector at the expense of pharmaceutical companies and tightening of existing drug approval requirements









Financial calendar 2025

Dermapharm



Disclaimer



This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, "Dermapharm") and such statements, estimates, opinions and projections ("Forward-Looking Statements") reflect various assumptions concerning anticipated results based on Dermapharm's current business plan or publicly available sources which have not been independently verified or assessed by Dermapharm and which may prove to be incorrect.

The Forward-Looking Statements reflect current expectations based on the current business plan and various other assumptions, involve significant risks and uncertainties, should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of whether or not such results will be achieved. The Forward-Looking Statements only speak as of the date of this publication. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of Dermapharm and the estimates given herein. These factors include those discussed in Dermapharm's financial statements which are available on Dermapharm's website. Each recipient of this publication should make its own assessment of the validity of Forward-Looking Statements and other assumptions and, Dermapharm accepts no liability with respect to any Forward-Looking Statements or other assumptions.

Except as provided by law, Dermapharm assumes no obligation whatsoever to update or revise any of the information, Forward-Looking Statements and conclusions contained herein, or to reflect new events or circumstances or to correct any inaccuracies which may become apparent subsequent to the date hereof.

For information, please contact

Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE

E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233

